Bioreductive Activation
Bioreductive Activation is a prodrug activation mechanism in which enzymatic reduction under hypoxic or low-redox conditions selectively converts an inactive prodrug into its active cytotoxic form, distinguishing it from other activation mechanisms by its reliance on cellular reductases and oxygen-sensitive biotransformation.
87
Publications
6.2K
Citations
403
Authors
125
Institutions
Publications per year
2017–2026
8
87
Kunal Nepali, Hsueh‐Yun Lee, Jing‐Ping Liou · Journal of Medicinal Chemistry · 2018 · 618 citations · Full text
Ujjini H. Manjunatha, Helena I. Boshoff, Cynthia S. Dowd et al. · Proceedings of the National Academy of Sciences · 2005 · 332 citations · Full text
Sara A. Fitzsimmons, Paul Workman, Michael R. Grever et al. · JNCI Journal of the National Cancer Institute · 1996 · 235 citations · Full text
1–5 of 87
403
7
h-index
7
h-index
7
h-index
6
h-index
5
h-index
1–5 of 403
125

University of Auckland
Auckland, New Zealand
12 h-index
55 publications
4.5K citations
Cancer Society of New Zealand
Wellington, New Zealand
7 h-index
45 publications
4K citations
University of Colorado Health
Aurora, United States
5 h-index
5 publications
514 citations

Cancer Research UK
London, United Kingdom
4 h-index
17 publications
776 citations

University of Bradford
Bradford, United Kingdom
4 h-index
17 publications
522 citations
Yale University
New Haven, United States
4 h-index
17 publications
887 citations
University of Missouri
Columbia, United States
3 h-index
17 publications
714 citations
Maurice Wilkins Centre
Auckland, New Zealand
3 h-index
13 publications
561 citations
1–8 of 125
Repository · 18 publications · 1.1K citations
16
h-index
7 publications · 1.1K citations
7
h-index
BJC · 5 publications · 261 citations
5
h-index
JACS · 3 publications · 215 citations
3
h-index
3 publications · 154 citations
3
h-index
1–5